Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

AstraZeneca200 enrolled

Overview

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Breast Cancer

Interventions

FulvestrantDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive HR or ER by immunohistochemistry * Postmenopausal status at the time of treatment with fulvestrant * Failure of at least one previous endocrine therapy before treatment with fulvestrant. Exclusion Criteria: * Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study

Locations (4)

Research Site

Recife, Pernambuco, Brazil

Research Site

Rio de Janeiro, Rio de Janeiro, Brazil

Research Site

Porto Alegre, Rio Grande do Sul, Brazil

Research Site

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

Time to tumour progression

Objective response

Secondary Outcomes

Duration of treatment with fulvestrant

Time and duration of response

Overall survival

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.